Collegium Pharmaceutical (COLL) has provided an update.
Collegium Pharmaceutical, Inc. finalized its acquisition of Ironshore Therapeutics Inc. on September 3, 2024, with a merger deal valued at approximately $525 million in cash and an additional potential milestone payment of $25 million. To fund this acquisition, Collegium secured a $325 million loan from BioPharma Credit PLC and associated lenders. The completion of the deal was publicly announced via a press release and detailed in a corporate presentation on the company’s website.
Find detailed analytics on COLL stock on TipRanks’ Stock Analysis page.
